Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer’s drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than the placebo group. These results have been described as a ‘historic moment for dementia research’—but what do they really mean for patients?

This post was originally published on this site

Skip The Dishes Referral Code

KeyLegal.ca - Consult a Lawyer Online in a variety of legal subjects